Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IV Bevacizumab Treatment of Patients With Hereditary Hemorrhagic Telangiectasia or Rendu-Osler Disease: A Retrospective Analysis of French Cohort Data From 2009 to 2024

NCT07772050 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT07772050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07772050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IV Bevacizumab Treatment of Patients With Hereditary Hemorrhagic Telangiectasia or Rendu-Osler Disease: A Retrospective Analysis of French Cohort Data From 2009 to 2024
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Completed
Start date
January 1, 2009
Completion date
December 31, 2025
Enrollment
244 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia (hht), rendu osler disease